Soleno Therapeutics announced that the FDA has granted Fast Track designation to Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi Syndrome (PWS). Soleno is currently conducting a Phase III clinical trial of DCCR for the treatment of PWS. Fast Track designation allows additional meetings with the FDA to discuss Soleno’s development plan to ensure the appropriate data are collected and encourages frequent written communication with the FDA regarding design of cl...